173 related articles for article (PubMed ID: 15652753)
1. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Shaked Y; Bertolini F; Man S; Rogers MS; Cervi D; Foutz T; Rawn K; Voskas D; Dumont DJ; Ben-David Y; Lawler J; Henkin J; Huber J; Hicklin DJ; D'Amato RJ; Kerbel RS
Cancer Cell; 2005 Jan; 7(1):101-11. PubMed ID: 15652753
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
4. Circulating endothelial cells as biomarkers in clinical oncology.
Mancuso P; Bertolini F
Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
[TBL] [Abstract][Full Text] [Related]
6. A surrogate marker to monitor angiogenesis at last.
Schneider M; Tjwa M; Carmeliet P
Cancer Cell; 2005 Jan; 7(1):3-4. PubMed ID: 15652744
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
Thejass P; Kuttan G
Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
11. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
12. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
[TBL] [Abstract][Full Text] [Related]
13. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.
Monestiroli S; Mancuso P; Burlini A; Pruneri G; Dell'Agnola C; Gobbi A; Martinelli G; Bertolini F
Cancer Res; 2001 Jun; 61(11):4341-4. PubMed ID: 11389057
[TBL] [Abstract][Full Text] [Related]
15. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
16. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
17. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis.
Zou GM; Karikari C; Kabe Y; Handa H; Anders RA; Maitra A
J Cell Physiol; 2009 Apr; 219(1):209-18. PubMed ID: 19097035
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
20. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
